ACELRX PHARMACEUT. DL-01 (R5XA) — Net Asset Quality Index
ACELRX PHARMACEUT. DL-01 (R5XA) has a Net Asset Quality Index of 57.3% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €29.72 Million minus total liabilities of €12.68 Million yields net assets of €17.04 Million. A higher index indicates a stronger, lower-leverage balance sheet. See R5XA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
ACELRX PHARMACEUT. DL-01 Net Asset Quality Index Over Time (2021–2025)
This chart shows how ACELRX PHARMACEUT. DL-01's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 57.3%, representing net assets of €17.04 Million against total assets of €29.72 Million EUR. Explore R5XA cash flow conversion to assess how effectively this company generates cash.
Annual Net Asset Quality Index for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for ACELRX PHARMACEUT. DL-01 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see ACELRX PHARMACEUT. DL-01 (R5XA) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 57.3% | €17.04 Million | €29.72 Million | €12.68 Million | ▲ +13.4 pp |
| 2024 | 43.9% | €8.00 Million | €18.24 Million | €10.23 Million | ▼ -25.3 pp |
| 2023 | 69.2% | €14.11 Million | €20.39 Million | €6.29 Million | ▲ +23.2 pp |
| 2022 | 45.9% | €21.81 Million | €47.49 Million | €25.67 Million | ▲ +92.0 pp |
| 2021 | -46.1% | €-35.89 Million | €77.89 Million | €113.79 Million | — |